Cytogenetic changes of human T-lymphotropic virus type I infected human lymphocytes transformed by carcinogen treatment (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cytogenetic changes of human T-lymphotropic virus type I infected human lymphocytes transformed by carcinogen treatment (Meeting abstract).

2nd International Conference on Gene Regulation/Oncogenesis/AIDS, September 23-30, 1993, Loutraki, Greece, p. 38, 1993.. Unique Identifier : AIDSLINE ICDB/95606698
Fukushima T; Mochizuki S; Kawamura K; Koshikawa N; Wang S; Miyauchi M; Maruyama K; Chiba Cancer Center Research Inst., Chiba, Japan


Abstract: A number of chromosomal abnormalities have been documented in ATL in which human T-lymphotropic virus type I (HTLV-I) has been implicated. In order to investigate the mechanism of transformation of HTLV-I infected cells, lymphocytes from an HTLV-I seronegative normal person were infected in vitro with HTLV-I. A continuous T cell line (Coculture-5) dependent on IL-2 for growth was established. Following treatment with MNNG and TPA, a subline (MNNG-TPA) dependent of TPA for growth was obtained. A subline (MNNG-I) of autonomously growing transformed cells was established following MNNG treatment of Coculture-5 cells. Other transformed cell lines (UV-1, -2, -3, -4, -5) were obtained following ultraviolet ray irradiation of Coculture-5 cells. Karyotype analyses revealed structural abnormalities characteristic of each line clustering to chromosomes 1 and 7, in addition to common abnormalities of chromosome 1 and 8. DNA of these cells subjected to RFLP analyses showed alterations in EcoRI fragments of met gene that is known to reside in chromosome 7, and to be associated with MNNG-induced transformation. Results of PCR-SSCP using specific primers for met gene suggested met gene alterations in cells transformed following treatment with MNNG. Results of ABC tests using specific antibodies indicated changes in expression of proteins coded by genes, including met residing in chromosomes with specific abnormalities, as well as those coded by genes related to the cell cycle including PCNA. Particular cytogenetic changes of HTLV-I infected cells appeared to be involved in their transformation following exposure to carcinogens.
Keywords: Carcinogens/*TOXICITY Cell Division Cell Transformation, Neoplastic Chromosomes, Human, Pair 7 Human *HTLV-I Lymphocytes/*VIROLOGY Methylnitronitrosoguanidine/*TOXICITY Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Tetradecanoylphorbol Acetate/*TOXICITY ABSTRACTKWDcarcinogens/KWDtoxicitycelldivisioncelltransformation,neoplasticchromosomes,human,pair7humanKWDhtlv-ilymphocytes/KWDvirologymethylnitronitrosoguanidine/KWDtoxicitypolymerasechainreactionpolymorphism,restrictionfragmentlengthtetradecanoylphorbolacetate/KWDtoxicityabstract
950430
M9541156

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .